Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical completes patient recruitment for its clinical program in the US
Non-regulatory
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSP…
Report from Sedana Medical’s annual general meeting on 22 May 2024
Regulatory
Sedana Medical AB (publ)’s annual general meeting was held on Wednesday, 22 May 2024 and the main re…
Sedana Medical AB's Interim report January-March 2024
Regulatory
Off to a strong start with record sales in Q1
Financial Calendar
| Annual General Meeting | 22 May 2024 | 14:00 |
| Interim Report Q2 2024 | 23 July 2024 | 07:00 |
